The landscape of targeted cancer therapy is undergoing a significant paradigm shift following recent clinical disclosures at the European Society…
Read More
Pfizer and Enodia Therapeutics Ink Multi-Million-Dollar Agreement to Advance Novel Sec61 Inhibitors in Major R&D Partnership
Pharmaceutical giant Pfizer has entered into a strategic research collaboration and licensing agreement with Enodia Therapeutics valued at upwards of…
Read More
Evogene and ELEO Forge Strategic Alliance to Pioneer Next-Generation Oral PCSK9 Inhibitors for Cardiovascular Disease
Evogene and ELEO have officially announced a significant scientific collaboration poised to accelerate the discovery and development of novel oral…
Read More
Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read More
